CancerFax

14/03/2026

What do NCCN guidelines say about NGS in 2026?

If you’re an oncologist wondering whether NGS is “recommended” or just “nice to have," let the guidelines speak.

Here’s a summary of current NCCN recommendations for comprehensive genomic profiling:

NSCLC (Non-Small Cell Lung Cancer):
“Broad molecular profiling is recommended for all patients with advanced NSCLC.”
That means NGS is not a sequential single-gene testing.

Breast Cancer:
Germline BRCA1/2 testing for all eligible patients. Somatic PIK3CA, ESR1, and HER2 testing for advanced disease. NGS panels capture all of these in one test.

Colorectal Cancer:
Universal MMR/MSI testing. RAS and BRAF testing for metastatic disease. HER2 amplification assessment. NGS covers the full panel.

Ovarian Cancer:
Germline and somatic BRCA + HRD testing for all patients with epithelial ovarian cancer. This testing is crucial in making decisions about PARP inhibitors.

Hematological Malignancies:
AML: FLT3, IDH1/2, NPM1, TP53 at diagnosis. ALL: Broad molecular characterization. CML: BCR-ABL monitoring.

The message from global guidelines is clear: comprehensive genomic testing is no longer optional for quality cancer care. It's a must.

10/03/2026

Here’s a number that should change how we think about cancer treatment:

NGS results change the treatment plan in 30–40% of advanced cancer cases.

Let that sink in. For roughly 1 in 3 patients with advanced cancer, comprehensive genomic profiling reveals something that directly alters the course of treatment.

What does “change the treatment plan” actually mean?

• A patient scheduled for standard chemotherapy gets matched to a targeted therapy with better outcomes and fewer side effects.
• A patient with no known options gets identified for a clinical trial based on a rare but druggable mutation.
• A patient is spared an ineffective treatment because their molecular profile predicts resistance.

This isn’t theoretical. This is published evidence from studies across lung, breast, colorectal, and ovarian cancers.

In India, where we see over 14 lakh new cancer cases every year, this translates to lakhs of patients who could benefit from precision diagnostics.

The question isn’t whether NGS works. It’s whether we can afford not to use it.

What’s your experience? Have genomic results ever changed your treatment approach?

09/03/2026

✨ A powerful example of what precision oncology can achieve ✨

A published clinical case from China showed a patient with huge, unresectable hepatocellular carcinoma (HCC) achieving a remarkable and long-lasting response using p53 gene therapy (Gendicine®) combined with TACE and chemotherapy.

🔬 Key highlights:
• Tumor size reduced from 16 × 13.5 cm to just 3 × 2 cm
• AFP levels dropped from 12,947 to normal
• Liver function remained stable
• Disease control sustained for over 600 days

This case reinforces the role of TP53-targeted gene therapy in sensitizing tumors to chemotherapy and improving outcomes in advanced HCC patients who are not surgical candidates.

📚 Published in Anti-Cancer Drugs (2009)

As oncology moves beyond one-size-fits-all treatments, gene therapy is redefining what’s possible in advanced liver cancer.

06/03/2026

Every cancer has a genetic story behind it. NGS, or next-generation sequencing, helps us read that story and choose therapies that truly match the biology of the disease, allowing for personalized treatment plans that can significantly improve patient outcomes.

At CancerFax, we strongly believe genomic testing should become a routine part of cancer care so patients can access the most precise and effective treatment options available today.

From DNA to Drug Selection: How NGS Actually Works?

Your patient has advanced cancer. You suspect there might be a targeted mutation. Here’s what happens when you order NGS (next-generation sequencing):

Step 1: Sample Collection
Tumor tissue (biopsy or surgical specimen) or a liquid biopsy (blood draw) is collected.

Step 2: DNA Extraction
Genomic DNA is extracted from tumor cells and fragmented into millions of small pieces.

Step 3: Library Preparation
DNA fragments are tagged and prepared for sequencing. Target genes are captured using a panel (e.g., 300–500 cancer-related genes).

Step 4: Sequencing
Millions of DNA fragments are read simultaneously; this is the “next-generation” part. Unlike Sanger sequencing (1 gene at a time), NGS reads thousands of genes in parallel.

Step 5: Bioinformatics Analysis
Sophisticated algorithms compare the tumor DNA to a reference genome, identifying mutations, fusions, copy number changes, TMB, and MSI status.

Step 6: Clinical Report
Results are compiled into an actionable report: which mutations were found, which therapies they respond to, and which clinical trials are available.

The entire process takes 7–14 days from sample to report.

One test. Hundreds of answers. That’s the power of NGS.

Save this post. Share it with a colleague who’s curious about genomic testing.

03/03/2026

Quick question for my oncology colleagues in India:

How often do you currently order comprehensive genomic testing (NGS) for your advanced cancer patients?

🟢 Always: It’s part of my standard workup
🟡 Sometimes: For specific cancer types or when standard therapy fails
🟠 Rarely: Cost and access are barriers
🔴 Never: I’m not sure when it’s indicated

No judgment here. This is about understanding our community's status so we can plan our next steps.

Drop your thoughts in the comments. What's the biggest barrier you face?

Results from this poll will shape the content we share in the coming weeks.

hashtag hashtag hashtag hashtag hashtag

24/02/2026

Single-gene testing vs. NGS panel testing: here’s what every oncologist should know.

The old approach: test one gene at a time.
• EGFR first. Wait 5–7 days.
• Negative? Try ALK. Wait again.
• Still negative? Test ROS1. More waiting.
• Weeks lost. Tissue depleted. Options narrowing.

The NGS approach: test 800+ genes simultaneously.
• One sample. One test. One comprehensive report.
• Actionable mutations, fusions, amplifications, TMB, MSI all at once.
• The report provides results that directly correspond to approved therapies and clinical trials.

Single-gene testing misses up to 50% of actionable alterations that NGS would catch.

In 2026, can we afford to test one gene at a time?

Swipe through the carousel to see the full comparison. Consider saving it for your next tumor board.

17/02/2026

Your patient’s cancer has a name. But does it have an address?

We say “lung cancer” or “breast cancer.” But oncology has moved far beyond organ-based classifications.

Today, we know that two patients with the same diagnosis can have wildly different molecular profiles and wildly different responses to the same treatment.

One patient’s “lung cancer” might harbor an EGFR mutation that responds beautifully to targeted therapy. Another might carry an ALK fusion that needs a completely different approach. A third might have no known driver mutation at all.

Same organ. Same histology. Three different molecular diseases.

This is why genomic testing isn’t a luxury; it's the lens through which modern oncology must operate.

Next-Generation Sequencing (NGS) doesn’t just name the cancer. It gives you the molecular address so you can deliver the right therapy to the right patient.

Over the next 4 weeks, we’re going to break down everything Indian oncologists need to know about NGS testing, the science, the evidence, the guidelines, and why it matters for your patients.

Follow along. This is the DecodeTheCancer series by CancerFax.

11/02/2026

🚀 Exciting News—CancerFax Featured in USA News!

We're proud to share that CancerFax has been featured in USA News in a powerful story titled "From Personal Loss to Global Impact: CancerFax Revolutionizes Access to Advanced Cancer Treatment."

The piece highlights how CancerFax was born out of a deeply personal experience with cancer and how that journey fueled a mission to transform the way patients around the world access cutting-edge cancer treatments, including CAR-T cell therapy and other advanced immunotherapies.

Here's what the article covers:

Our Origin Story: How personal loss became the catalyst for building a platform dedicated to bridging the gap between cancer patients and life-saving treatments.

Breaking Barriers: CancerFax is making advanced cancer therapies once limited to a few countries and institutions accessible to patients globally, helping them navigate treatment options, clinical trials, and top oncology centers worldwide.

A Global Mission: Our commitment to ensuring that geography and financial constraints don't stand between a patient and the best possible care.

This recognition reaffirms our dedication to every patient and family navigating a cancer diagnosis. We're just getting started.

🔗 Read the full article here: https://bit.ly/4qvmZCe

CancerFax delivers advanced cancer care with global connections and therapies, offering hope and healing in tough times.

05/02/2026

🧬 Breakthrough: 100% Response Rate in Advanced Cervical Cancer Study!

Are you or a loved one seeking the latest advancements in treatment? A landmark Phase II study has revealed a major breakthrough for patients with stage IIB-IVA locally advanced cervical carcinoma.

The Key Finding:
When standard radiotherapy was combined with weekly intratumoral injections of rAd-p53 gene therapy (Gendicine), the overall response rate reached a staggering 100%, compared to just 72.2% with radiation alone.

Why This Matters:

Superior Efficacy: Over 52% of patients in the gene therapy group achieved a Complete Response (CR).

Enhanced Safety: The therapy was well-tolerated, with the most common side effect being a manageable, self-limited fever.

Zero Progression: No patients in the combination group saw their disease progress during the study period.

At CancerFax, we are dedicated to connecting patients worldwide with cutting-edge therapies like gene therapy, CAR T-cell therapy, and global clinical trials. Our end-to-end concierge service ensures you have access to the most advanced oncology centers in the USA, China, and beyond.

Don't settle for standard care when innovation is available.

🔗 Learn more about advanced treatment options at: https://cancerfax.com

Call/WhatsApp for a Free Consultation: (213) 789-5655

04/02/2026

Today, on World Cancer Day, we stand united in the fight against cancer. 💙

At CancerFax, we're committed to connecting patients with cutting-edge immunotherapy and cellular therapy treatments that offer new hope and possibilities. Every day, we work to bridge the gap between innovative cancer care and those who need it most.

This World Cancer Day, let's remember: early detection saves lives, research brings hope, and together, we are stronger than cancer.
To everyone affected by cancer—patients, survivors, caregivers, and medical professionals—we see you, we support you, and we're here for you.

Let's continue to push boundaries, share knowledge, and fight for a world where cancer is no longer a life sentence.

Together, we can close the care gap. 🌍

07/01/2026

Clinical Trials Alert | Chinese Academy of Medical Sciences, National Cancer Center

A new recruitment call is now open for a promising lung cancer clinical trial in China. Researchers at the National Cancer Center are evaluating a combination of inhaled mRNA vaccine with bevacizumab (VEGF/PD-1 bispecific antibody).

This study is enrolling patients with:
• Chemotherapy-resistant lung cancer
• Adenocarcinoma or squamous cell carcinoma
• Cases with or without genetic mutations

The trial aims to investigate whether this dual-immunotherapy approach can enhance anti-tumor activity and open new options for patients who have limited treatment choices left.

If you or someone you know is seeking advanced treatment pathways, this may be worth considering.

📩 For eligibility checks and enrollment support:

WeChat / WhatsApp: +86 182 1759 2149

CancerFax | Advanced Cancer Treatment Management

13/12/2025

Did you know China alone has over 18,000 active clinical trials focused on cancer treatment right now?

Clinical trials are not blind experiments. They are carefully designed pathways that bring tomorrow’s treatments to patients today. From targeted therapies and immunotherapy to advanced cell and gene treatments, this is where real progress happens.

Are you curious about the workings of clinical trials? We are taking you behind the scenes with insights from researchers, doctors, and real patient experiences that show what participation truly looks like.

If you or a loved one is exploring advanced treatment options, this section is worth a closer look.

👉 Explore ongoing cancer clinical trials here:

https://cancerfax.com/clinical-trials/

Uncover the power of cancer clinical Trials in China! Discover how they shape treatment strategies. Learn about effectiveness & side Effects of our clinical trials.